EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options

Sakshi Jhawar, Abhishek Jha, Sara Talvacchio, Junne Kamihara, Jaydira Del Rivero, Karel Pacak

Clinical Endocrinology · 2025-06 · 102 (6) · 626-634

DOI: 10.1111/cen.15212 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Endocrinology, online erschienen am 17.03.2025. Verfasst von Sakshi Jhawar und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Adrenal Gland Neoplasms, Paraganglioma, Pheochromocytoma, Receptor, Fibroblast Growth Factor, Type 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pheochromocytoma and paraganglioma (together PPGL) are tumours with a high degree of heritability. Genetic landscape is divided into three clusters, cluster 1 (Krebs/pseudohypoxia signalling pathway), cluster 2 (kinase signalling pathway) and cluster 3 (Wnt signalling pathway). With increasing knowledge in the field of genetics, cluster‐specific tumour characteristics, biochemical phenotype and imaging signatures are established in commonly found genes. The association of FGFR1 pathogenic mutations with PPGL have been recently described although its features are not yet well established. Here, we present four patients with PPGL who were found to have somatic FGFR1 pathogenic mutations. We discuss their clinical presentations, biochemical phenotypes, imaging signatures and treatment options that will be relevant for practicing physicians in managing these patients effectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Gland NeoplasmsParagangliomaPheochromocytomaReceptor, Fibroblast Growth Factor, Type 1HumansMutation

Stichwörter der Autor:innen

FGFR1biochemical phenotypegeneticsimaging phenotypeparagangliomapheochromocytoma

Substanzen

FGFR1 protein, humanReceptor, Fibroblast Growth Factor, Type 1

Autor:innen und Institutionen

  • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts, USA.
  • National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Zitieren

APA

Jhawar, S., Jha, A., Talvacchio, S., Kamihara, J., Del Rivero, J., & Pacak, K. (2025). Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options. Clinical Endocrinology, 102(6), 626-634. https://doi.org/10.1111/cen.15212

Vancouver

Jhawar S, Jha A, Talvacchio S, Kamihara J, Del Rivero J, Pacak K. Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options. Clinical Endocrinology. 2025;102(6):626-634. doi:10.1111/cen.15212

BibTeX
@article{Jhawar2025,
  author = {Jhawar, Sakshi and Jha, Abhishek and Talvacchio, Sara and Kamihara, Junne and Del Rivero, Jaydira and Pacak, Karel},
  title = {Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options},
  journal = {Clinical Endocrinology},
  year = {2025},
  volume = {102},
  number = {6},
  pages = {626--634},
  doi = {10.1111/cen.15212}
}
Kostenlos starten →